Journal
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
Volume 33, Issue 1, Pages 5-15Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14767058.2018.1484089
Keywords
Apela; maternal vascular malperfusion; maternal vascular underperfusion; placenta; pregnancy; preterm delivery
Categories
Funding
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002400] Funding Source: NIH RePORTER
- Intramural NIH HHS [ZIA HD002400-26] Funding Source: Medline
- NICHD NIH HHS [HHSN275201300006C] Funding Source: Medline
Ask authors/readers for more resources
Objective: ELABELA is a newly discovered peptide hormone that appears to be implicated in the mechanisms leading to preeclampsia, independently of angiogenic factors. The aim of the current study was to investigate whether women with early- or late-onset preeclampsia have altered ELABELA plasma concentrations compared to gestational-age-matched normal pregnant women. Methods: This retrospective cross-sectional study focused on the maternal plasma samples collected from 232 women with a singleton pregnancy who were allocated into the following groups: (1) early-onset preeclampsia (<34?weeks of gestation, N?=?56); (2) late-onset preeclampsia (?34?weeks of gestation, N?=?57); and (3) gestational-age-matched controls with a normal pregnancy [(<34?weeks of gestation, N?=?59); (?34?weeks of gestation, N?=?60)]. ELABELA plasma concentrations were determined using a validated enzyme immunoassay. Results: (1) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared with those from gestational-age-matched controls with a normal pregnancy [median: 7.99?ng/mL (IQR, 5.3?13.95?ng/mL) versus median: 4.17?ng/mL (IQR, 3?11.19?ng/mL), p =.001]; (2) ELABELA plasma concentrations in patients with early-onset preeclampsia do not differ from those of normal pregnant women [median: 6.09?ng/mL (IQR, 2.8?10.66?ng/mL) versus median: 4.02?ng/mL (IQR, 3.26?7.49), p?=?.32]; and (3) ELABELA plasma concentrations are higher in patients with late-onset preeclampsia compared to those with early-onset preeclampsia [median: 7.99?ng/mL (IQR, 5.3?13.95?ng/mL) versus median: 6.09?ng/mL (IQR, 2.8?10.66?ng/mL), p?=?.01]. Conclusion: ELABELA plasma concentrations are higher in patients with late-onset preeclampsia than in those with a normal pregnancy. However, women with early-onset preeclampsia have similar ELABELA plasma concentrations to those with a normal pregnancy. These findings provide insight into the ELABELA axis during the human syndrome of preeclampsia. In addition, these data support the concept that different pathophysiologic mechanisms are implicated in early- and late-onset preeclampsia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available